Tuberculosis in renal transplant recipients on various immunosuppressive regimens
Articles > Article · 2005
Authors: Alev GÜRGÜN, FEZA BACAKOĞLU, Hüseyin TÖZ, Özen KAÇMAZ BAŞOĞLU, Soner DUMAN, K BASAK, A GUZELANT, Abdullah SAYINER
NEPHROLOGY DIALYSIS TRANSPLANTATION, Journal Indexed in SCI Expanded, International, 2005, vol 20, pp 797-802
DOI: 10.1093/ndt/gfh691
Summary
Background. Mycophenolate mofetil (MMF) and tacrolimus (TAC) are more potent than conventional immunosuppressive drugs, i.e. azathioprine, cyclosporin and prednisolone, and may be associated with an increase in the incidence of infections in the post-transplantation (post-tx) period. The aim of this study was to determine if the use of either or both of MMF and TAC for immunosuppression in renal transplant recipients increases the prevalence or modifies the clinical presentation of tuberculosis (TB), when compared with conventional therapy.